Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
22
09
2021
accepted:
22
02
2022
revised:
21
02
2022
pubmed:
19
3
2022
medline:
22
4
2022
entrez:
18
3
2022
Statut:
ppublish
Résumé
Lysergic acid diethylamide (LSD) is a serotonergic psychedelic compound receiving increasing interest due to putative anxiolytic and antidepressant properties. However, the potential neurobiological mechanisms mediating these effects remain elusive. Employing in vivo electrophysiology, microionthophoresis, behavioral paradigms and morphology assays, we assessed the impact of acute and chronic LSD administration on anxiety-like behavior, on the cortical dendritic spines and on the activity of serotonin (5-HT) neurons originating in the dorsal raphe nucleus (DRN) in male mice exposed to chronic restraint stress. We found that while the acute intraperitoneal (i.p.) administration of LSD (5, 15 and 30 and 60 μg/kg) did not produce any anxiolytic or antidepressant effects in non-stressed mice, the dose of 30 µg/kg (daily for 7 days) prevented the stress-induced anxiety-like behavior and the stress-induced decrease of cortical spine densitiy. Interestingly, while LSD acutely decreased the firing activity of 5-HT neurons, repeated LSD increased their basal firing rate and restored the low 5-HT firing induced by stress. This effect was accompanied by a decreased inhibitory response of 5-HT neurons to microiontophoretic applications of the 5-HT
Identifiants
pubmed: 35301424
doi: 10.1038/s41386-022-01301-9
pii: 10.1038/s41386-022-01301-9
pmc: PMC9018770
doi:
Substances chimiques
Anti-Anxiety Agents
0
Antidepressive Agents
0
Hallucinogens
0
Serotonin
333DO1RDJY
Lysergic Acid Diethylamide
8NA5SWF92O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1188-1198Subventions
Organisme : CIHR
ID : 436986
Pays : Canada
Informations de copyright
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
Nutt D. Psychedelic drugs-a new era inpsychiatry? Dialogues Clin Neurosci. 2019;21:139–47.
doi: 10.31887/DCNS.2019.21.2/dnutt
pubmed: 31636488
pmcid: 6787540
Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharm Rev. 2021;73:202–77.
doi: 10.1124/pharmrev.120.000056
pubmed: 33328244
Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611–24.
doi: 10.1038/s41583-020-0367-2
pubmed: 32929261
Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638.
doi: 10.1038/npp.2016.82
pubmed: 27249781
pmcid: 5026740
Mueller F, Lenz C, Dolder PC, Harder S, Schmid Y, Lang UE, et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017;7:e1084.
doi: 10.1038/tp.2017.54
pubmed: 28375205
pmcid: 5416695
Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 2018;235:535–45.
doi: 10.1007/s00213-017-4733-3
pubmed: 28918441
Carhart-Harris RL, Kaelen M, Bolstridge M, Williams T, Williams L, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychological Med. 2016;46:1379–90.
doi: 10.1017/S0033291715002901
Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29:57–68.
doi: 10.1177/0269881114555249
pubmed: 25389218
Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513.
doi: 10.1097/NMD.0000000000000113
pubmed: 24594678
pmcid: 4086777
ClinicalTrials.gov. LSD therapy for persons suffering from major depression (LAD). ClinicalTrials.gov Identifier: NCT03866252; https://clinicaltrials.gov/ct2/show/NCT03866252 . 2019.
De Gregorio D, Posa L, Ochoa-Sanchez R, McLaughlin R, Maione S, Comai S, et al. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol Res. 2016;113:81–91.
doi: 10.1016/j.phrs.2016.08.022
pubmed: 27544651
De Gregorio D, Comai S, Posa L, Gobbi G. d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. Int J Mol Sci. 2016;17:1953.
doi: 10.3390/ijms17111953
pmcid: 5133947
Marona-Lewicka D, Chemel BR, Nichols DE. Dopamine D 4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology. 2009;203:265–77.
doi: 10.1007/s00213-008-1238-0
pubmed: 18604600
Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD. Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology. 2014;83:1–8.
doi: 10.1016/j.neuropharm.2014.03.013
pubmed: 24704148
pmcid: 4098645
De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, et al. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci. 2021;118:e2020705118.
Lowry CA, Hale MW, Evans AK, Heerkens J, Staub DR, Gasser PJ, et al. Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci. 2008;1148:86–94.
doi: 10.1196/annals.1410.004
pubmed: 19120094
Nishitani N, Nagayasu K, Asaoka N, Yamashiro M, Andoh C, Nagai Y, et al. Manipulation of dorsal raphe serotonergic neurons modulates active coping to inescapable stress and anxiety-related behaviors in mice and rats. Neuropsychopharmacology. 2019;44:721–32.
doi: 10.1038/s41386-018-0254-y
pubmed: 30377380
Bambico FR, Nguyen N-T, Gobbi G. Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress. Eur Neuropsychopharmacol. 2009;19:215–28.
doi: 10.1016/j.euroneuro.2008.11.005
pubmed: 19147333
Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109.
doi: 10.1038/sj.npp.1301574
pubmed: 17851537
Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18:1125–35.
doi: 10.1038/mp.2012.90
pubmed: 22776900
Aghajanian GK, Foote WE, Sheard MH. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science. 1968;161:706–08.
doi: 10.1126/science.161.3842.706
pubmed: 4874578
De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, et al. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci. 2021;118:e2020705118.
doi: 10.1073/pnas.2020705118
pubmed: 33495318
pmcid: 7865169
Borison RL, Havdala HS, Diamond BI. Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia? Life Sci. 1977;21:117–22.
doi: 10.1016/0024-3205(77)90431-3
pubmed: 560609
Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238–49.
doi: 10.1038/nm.4050
pubmed: 26937618
pmcid: 5405628
Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2012;13:22–37.
doi: 10.1038/nrn3138
Liston C, Miller MM, Goldwater DS, Radley JJ, Rocher AB, Hof PR, et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci. 2006;26:7870–74.
doi: 10.1523/JNEUROSCI.1184-06.2006
pubmed: 16870732
pmcid: 6674229
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.
doi: 10.1016/j.celrep.2018.05.022
pubmed: 29898390
pmcid: 6082376
Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994;15:220–6.
doi: 10.1016/0165-6147(94)90315-8
pubmed: 7940983
Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996;19:378–83.
doi: 10.1016/S0166-2236(96)10037-0
pubmed: 8873352
Aghajanian GK, Foote WE, Sheard MH. Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Exp Therap. 1970;171:178–87.
Haigler HJ, Aghajanian GK. Mescaline and LSD: direct and indirect effects on serotonin-containing neurons in brain. Eur J Pharmacol. 1973;21:53–60.
doi: 10.1016/0014-2999(73)90206-9
pubmed: 4709205
Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides. 2005;26:1383–93.
doi: 10.1016/j.peptides.2005.03.032
pubmed: 16042978
Bambico FR, Cassano T, Dominguez-Lopez S, Katz N, Walker CD, Piomelli D, et al. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology. 2010;35:2083–100.
doi: 10.1038/npp.2010.80
pubmed: 20571484
pmcid: 3055302
Hedlund PB, Kelly L, Mazur C, Lovenberg T, Sutcliffe JG, Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur J Pharmacol. 2004;487:125–32.
doi: 10.1016/j.ejphar.2004.01.031
pubmed: 15033384
Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A. 8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology. 2004;46:52–62.
doi: 10.1016/j.neuropharm.2003.08.007
pubmed: 14654097
Nikiforuk A, Kos T, Fijał K, Hołuj M, Rafa D, Popik P. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013;8:e66695.
doi: 10.1371/journal.pone.0066695
pubmed: 23776692
pmcid: 3679060
Guscott M, Egan E, Cook G, Stanton J, Beer M, Rosahl T, et al. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology. 2003;44:1031–37.
doi: 10.1016/S0028-3908(03)00117-5
pubmed: 12763096
Markopoulos A, Inserra A, De Gregorio D, Gobbi G. Evaluating the potential use of serotonergic psychedelics in autism spectrum disorder. Front Pharmacol. 2022;12:749068.
doi: 10.3389/fphar.2021.749068
pubmed: 35177979
pmcid: 8846292
dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therap Adv Psychopharmacol. 2016;6:193–213.
doi: 10.1177/2045125316638008
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–78.
doi: 10.1001/archgenpsychiatry.2010.116
pubmed: 20819978
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.
doi: 10.1177/0269881116675513
pubmed: 27909165
pmcid: 5367557
Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864–71.
doi: 10.1021/acschemneuro.9b00493
pubmed: 32133835
Buchborn T, Schröder H, Höllt V, Grecksch G. Repeated lysergic acid diethylamide in an animal model of depression: normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. J Psychopharmacol. 2014;28:545–52.
doi: 10.1177/0269881114531666
pubmed: 24785760
Vesuna S, Kauvar IV, Richman E, Gore F, Oskotsky T, Sava-Segal C, et al. Deep posteromedial cortical rhythm in dissociation. Nature. 2020;586:87–94.
doi: 10.1038/s41586-020-2731-9
pubmed: 32939091
pmcid: 7553818
Grossman L, Utterback E, Stewart A, Gaikwad S, Chung KM, Suciu C, et al. Characterization of behavioral and endocrine effects of LSD on zebrafish. Behavioural Brain Res. 2010;214:277–84.
doi: 10.1016/j.bbr.2010.05.039
Cameron LP, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N, N-Dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci. 2019;10:3261–70.
doi: 10.1021/acschemneuro.8b00692
pubmed: 30829033
Jefsen O, Højgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, et al. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta Neuropsychiatrica. 2019;31:213–19.
doi: 10.1017/neu.2019.15
pubmed: 31106729
Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:e2022489118.
Mahmoudi E, Faizi M, Hajiaghaee R, Razmi A. Alteration of depressive-like behaviors by psilocybe cubensis alkaloid extract in mice: the role of glutamate pathway. Res J Pharmacogn. 2018;5:17–24.
Wong M-L, Inserra A, Lewis M, Mastronardi CA, Leong L, Choo J, et al. Inflammasome signaling affects anxiety-and depressive-like behavior and gut microbiome composition. Mol Psychiatry. 2016;21:797–805.
doi: 10.1038/mp.2016.46
pubmed: 27090302
pmcid: 4879188
Strekalova T, Couch Y, Kholod N, Boyks M, Malin D, Leprince P, et al. Update in the methodology of the chronic stress paradigm: internal control matters. Behav Brain Funct. 2011;7:1–18.
doi: 10.1186/1744-9081-7-9
Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety-and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;39:112–19.
doi: 10.1016/j.pnpbp.2012.05.018
Li H, Buisman-Pijlman FTA, Nunez-Salces M, Christie S, Frisby CL, Inserra A, et al. Chronic stress induces hypersensitivity of murine gastric vagal afferents. Neurogastroenterol Motil. 2019;31:e13669.
pubmed: 31241809
doi: 10.1111/nmo.13669
Bambico FR, Belzung C. Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis? Curr Top Behav Neurosci. 2013;15:243–91.
doi: 10.1007/7854_2012_234
pubmed: 23271325
Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–64.
doi: 10.1126/science.1190287
pubmed: 20724638
pmcid: 3116441
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–9.
Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.
Morales-Garcia JA, Calleja-Conde J, Lopez-Moreno JA, Alonso-Gil S, Sanz-SanCristobal M, Riba J, et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry. 2020;10:331.
doi: 10.1038/s41398-020-01011-0
pubmed: 32989216
pmcid: 7522265
Inserra A, De Gregorio D, Rezai T, Lopez-Canul MG, Comai S, Gobbi G. Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice. J Psychopharmacol. 2021;35:469–82.
doi: 10.1177/0269881121991569
pubmed: 33645311
pmcid: 8058830
NRPW Hutten, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, et al. Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol Trans Sci. 2021;4:461–66.
doi: 10.1021/acsptsci.0c00099
Almeida RND, Galvão ACDM, da Silva FS, Silva EADS, Palhano-Fontes F, Maia-de-Oliveira JP, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol. 2019;10:1234.
Cini FA, Ornelas I, Marcos E, Goto-Silva L, Nascimento J, Ruschi S, et al. d-Lysergic acid diethylamide has major potential as a cognitive enhancer. bioRxiv. 2019, https://www.biorxiv.org/content/10.1101/866814v1 .
Willner P. Antidepressants and serotonergic neurotransmission: an integrative review. Psychopharmacology. 1985;85:387–404.
doi: 10.1007/BF00429653
pubmed: 2410942
Andrade R, Huereca D, Lyons JG, Andrade EM, McGregor KM. 5-HT1A receptor-mediated autoinhibition and the control of serotonergic cell firing. ACS Chem Neurosci. 2015;6:1110–15.
doi: 10.1021/acschemneuro.5b00034
pubmed: 25913021
Anyan J, Amir S. Too depressed to swim or too afraid to stop? A reinterpretation of the forced swim test as a measure of anxiety-like behavior. Neuropsychopharmacology. 2018;43:931–33.
doi: 10.1038/npp.2017.260
pubmed: 29210364
Molendijk ML, de Kloet ER. Coping with the forced swim stressor: current state-of-the-art. Behavioural brain Res. 2019;364:1–10.
doi: 10.1016/j.bbr.2019.02.005
Commons KG, Cholanians AB, Babb JA, Ehlinger DG. The rodent forced swim test measures stress-coping strategy, not depression-like behavior. ACS Chem Neurosci. 2017;8:955–60.
doi: 10.1021/acschemneuro.7b00042
pubmed: 28287253
Der-Avakian A, Mazei-Robison MS, Kesby JP, Nestler EJ, Markou A. Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response. Biol Psychiatry. 2014;76:542–49.
doi: 10.1016/j.biopsych.2014.01.013
pubmed: 24576687
pmcid: 4117827
Moreira PS, Almeida PR, Leite-Almeida H, Sousa N, Costa P. Impact of chronic stress protocols in learning and memory in rodents: systematic review and meta-analysis. PLoS One. 2016;11:e0163245.
doi: 10.1371/journal.pone.0163245
pubmed: 27662580
pmcid: 5035061
Patki G, Solanki N, Atrooz F, Allam F, Salim S. Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res. 2013;1539:73–86.
doi: 10.1016/j.brainres.2013.09.033
pubmed: 24096214
pmcid: 4316676
Meehan SM, Schechter MD. LSD produces conditioned place preference in male but not female fawn hooded rats. Pharmacol Biochem Behav. 1998;59:105–08.
doi: 10.1016/S0091-3057(97)00391-2
pubmed: 9443543